論文発表

Miyamoto, N.: Utilization of iPSC technologies for drug-induced risk and drug efficacy evaluation during drug development. Curr. Pharm. Biotechnol. 21 (9): 750 – 751 (2020).
Inoue, T., Iwazaki, N., Araki, T., and Hitotsumachi, H.: Human-induced pluripotent stem cell-derived hepatocytes and their culturing methods to maintain liver functions for pharmacokinetics and safety evaluation of pharmaceuticals. 21 (9): 773 – 779 (2020).
Shirakawa, T., and Suzuki, I.: Approach to neurotoxicity using human iPSC neurons: Consortium for Safety Assessment using Human iPS Cells. Curr. Pharm. Biotechnol. 21 (9): 780 – 786 (2020).
Matsui, T., Miyamoto, N., Saito, F., and Shinozawa, T.: Molecular profiling of human induced pluripotent stem cell-derived cells and their application for drug safety Study. Curr. Pharm. Biotechnol. 21 (9): 807 – 828 (2020).
Takasuna, K., Kazusa, K., and Hayakawa, T.: Comprehensive cardiac safety assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi). Curr. Pharm. Biotechnol. 21 (9): 829 – 841 (2020).
Yamazaki D., Kitaguchi T., Ishimura M., Taniguchi T., Yamanishi A., Saji D., Takahashi E., Oguchi M., Moriyama Y., Maeda S., Miyamoto K., Morimura K., Ohnaka H., Tashibu H., Sekino Y., Miyamoto N., Kanda Y.: Usefulness of human induced stem cell-derived cardiomyocytes for proarrhythmia risk prediction using 2-dimensional categorization system. J. Pharmacol Sci., 136: 249-256 (2018)
野﨑裕美子, ヒトiPS細胞由来心筋細胞を用いた新規催不整脈作用評価系の開発と有用性の検証．大阪大学大学院薬学研究科学位論文, (2017)
北口隆, ヒトiPS細胞由来心筋細胞と多電極アレイシステムを用いた薬剤誘発性QT間隔延長および催不整脈リスク予測評価法の検討．千葉大学大学院薬学研究院学位論文, (2017)
Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Tanaka K, Takahashi E, Miyamoto K, Morimura A, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Shinozawa T, Saito F, Kunimatsu T.: CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul. Toxicol. Pharmacol., 88: 238-251 (2017) .
Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N: CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods, 85: 73-81 (2017).
Takasuna K, Asakura K, Araki S, Ando H, Kazusa K, Kitaguchi T, Kunimatsu T, Suzuki S, Miyamoto N: Complehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi Heart initiative. J. Pharmacol. Toxicoll Methods, 83: 42-54 (2017).
宮本憲優：ヒト iPS 細胞由来分化細胞の安全性薬理試験への応用．実験医学, 34: 557-563 (2016).
Araki T, Iwazaki N, Ishiguro N, Sakamoto A, Nagata K, Ohbuchi M, Moriguchi H, Motoi M, Shinkyo R, Homma T, Sakamoto S, Iwase Y, Ise R, Nakanishi Y, Uto M, Inoue T: Requirements for human iPS cell-derived hepatocytes as an alternative to primary human hepatocytes for assessing absorption, distribution, metabolism, excretion and toxicity of pharmaceuticals. Fundamental Toxicol. Sci., 3: 89-99 (2016).
Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T: CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol., 77: 75-86 (2016).
Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Morita M, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Tanaka K, Washio I, Miyamoto N, CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia –Effects of 7 reference compounds at 10 facilities–. J. Pharmacol. Toxicoll Methods, 78: 93-102 (2016).
Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Nagasawa C, Kitamura T, Osada T, Honda Y, Kasai C, Ando H, Kanda Y, Sekino Y, Sawada K: Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J. Pharmacol. Toxicoll Methods, 75: 17-26 (2015).